Payment overview · 2025
General Payments
$81.73
5 reported records · 4 companies
Healthcare provider profile · identity verified
Gwendolyn Davis
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HELENA, AR · NPI 1700320173
Verified facts
What the public records show
CMS Open Payments records show Gwendolyn Davis received $81.73 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.99 | 39.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.10 | 20.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.88 | 20.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.76 | 19.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.73 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 161 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
159 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 694 | 180 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 688 | 155 |
| Omeprazole | Omeprazole | 625 | 200 |
| Promethazine Hcl | Promethazine Hcl | 514 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 110 |
| Sertraline Hcl | Sertraline Hcl | 275 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 100 |
| Penicillin V Potassium | Penicillin V Potassium | 226 | 86 |
| Meloxicam | Meloxicam | 207 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 48 |
| Metformin Hcl | Metformin Hcl | 194 | 52 |
| Methocarbamol | Methocarbamol | 184 | 69 |
| Prednisone | Prednisone | 179 | 100 |
| Glipizide | Glipizide | 177 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 174 | 55 |
| Simvastatin | Simvastatin | 173 | 47 |
| Furosemide | Furosemide | 170 | 49 |
| Potassium Chloride | Potassium Chloride | 166 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 64 |
| Farxiga | Dapagliflozin Propanediol | 161 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 161 | 61 |
| Mounjaro | Tirzepatide | 159 | 30 |
| Lisinopril | Lisinopril | 156 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 145 | 98 |
| Tramadol Hcl | Tramadol Hcl | 145 | 53 |
| Losartan Potassium | Losartan Potassium | 142 | 46 |
| Alendronate Sodium | Alendronate Sodium | 137 | 39 |
| Azithromycin | Azithromycin | 136 | 83 |
| Ozempic | Semaglutide | 134 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 36 |
| Fluconazole | Fluconazole | 118 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 118 | 39 |
| Lactulose | Lactulose | 117 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 27 |
| Linzess | Linaclotide | 91 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 23 |
| Ibuprofen | Ibuprofen | 85 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 26 |
| Mupirocin | Mupirocin | 84 | 55 |
| Allopurinol | Allopurinol | 80 | 31 |
| Jardiance | Empagliflozin | 79 | 21 |
| Eliquis | Apixaban | 76 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 33 |
| Famotidine | Famotidine | 59 | 23 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | 16 |
| Buspirone Hcl | Buspirone Hcl | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 54 | 18 |
| Nifedipine Er | Nifedipine | 52 | 19 |
| Baclofen | Baclofen | 51 | 21 |
| Acyclovir | Acyclovir | 50 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 17 |
| Cefdinir | Cefdinir | 47 | 34 |
| Diazepam | Diazepam | 47 | 21 |
| Levofloxacin | Levofloxacin | 46 | 40 |
| Temazepam | Temazepam | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 17 |
| Carvedilol | Carvedilol | 43 | 17 |
| Clonidine Hcl | Clonidine Hcl | 41 | 15 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 40 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Ondansetron Odt | Ondansetron | 38 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 12 |
| Levemir Flexpen | Insulin Detemir | 32 | 11 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 26 |
| Constulose | Lactulose | 30 | 16 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 12 |
| Indomethacin | Indomethacin | 28 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Cephalexin | Cephalexin | 21 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | 11 |
| Lumigan | Bimatoprost | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.73 · 5 records | Novo Nordisk Inc | FARXIGA, Flexitouch Plus, MOUNJARO, Nimbl, Ozempic, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error